As on Thursday, Keros Therapeutics Inc (NASDAQ: KROS) got off with the flyer as it spiked 6.61% to $15.17, before settling in for the price of $14.23 at the close. Taking a more long-term approach, KROS posted a 52-week range of $9.12-$72.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -48.13%. Meanwhile, its Annual Earning per share during the time was -48.13%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 112.67%. This publicly-traded company’s shares outstanding now amounts to $40.62 million, simultaneously with a float of $33.98 million. The organization now has a market capitalization sitting at $616.14 million. At the time of writing, stock’s 50-day Moving Average stood at $14.01, while the 200-day Moving Average is $20.02.
Keros Therapeutics Inc (KROS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Keros Therapeutics Inc’s current insider ownership accounts for 16.33%, in contrast to 87.30% institutional ownership. According to the most recent insider trade that took place on Apr 09 ’25, this organization’s 10% Owner bought 934,258 shares at the rate of 10.13, making the entire transaction reach 9,464,512 in total value, affecting insider ownership by 4,392,737.
Keros Therapeutics Inc (KROS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
Keros Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 112.67% and is forecasted to reach -4.20 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 3.09% through the next 5 years, which can be compared against the -48.13% growth it accomplished over the previous five years trading on the market.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Let’s observe the current performance indicators for Keros Therapeutics Inc (KROS). It’s Quick Ratio in the last reported quarter now stands at 21.11. Alongside those numbers, its PE Ratio stands at $48.42, and its Beta score is 1.06. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.65. Similarly, its price to free cash flow for trailing twelve months is now 11.61.
In the same vein, KROS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.31, a figure that is expected to reach -1.00 in the next quarter, and analysts are predicting that it will be -4.20 at the market close of one year from today.
Technical Analysis of Keros Therapeutics Inc (KROS)
Through scrutinizing the latest numbers posted by the [Keros Therapeutics Inc, KROS], it can be observed that its last 5-days Average volume of 0.6 million was lower the volume of 0.98 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 75.02% While, its Average True Range was 67.66%.
Raw Stochastic average of Keros Therapeutics Inc (KROS) in the period of the previous 100 days is set at 96.34%, which indicates a major rise in contrast to 90.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.59 that was higher than 0.56 volatility it exhibited in the past 100-days period.
